Evaluation of the effect of gluten-free diet on fatty liver, fat profile, weight, waist circumference, liver enzymes and blood pressure

Assessment of gluten free diet effect on hepatic steatosis, lipid profile, fasting blood sugar, blood pressure and anthropometric indexes in patients with non alcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201204049599N2

Enrollment

Registered

2021-04-01

Start date

2021-04-04

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: People with non-alcoholic fatty liver disease(NAFLD) will be studied if they do not meet the exclusion criteria and contain the inclusion criteria. The intervention

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age older than 18 years & younger than 60 years Having informed consent Ability of participation in study and adherence to gluten free diet Proof of NAFLD(Non-alcoholic fatty liver disease ) based on AASLD(American Association for the Study of Liver Diseases) criteria Patient should not having any of exclusion criteria

Exclusion criteria

Exclusion criteria: Lipid lowering agent Consumption oral corticosteroid agent Consumption Having diabetes mellitus or glucose lowering agent Consumption Having inflammatory bowel disease(IBD), infectious or organic gastrointestinal disease or IBS(Irritable bowel syndrome) Having coeliac disease Having Cirrhosis Daily ethanol Consumption more than 20 g for men & more than 10 g for women Having thyroid disorders or thyroid disease related agent Consumption Pregnancy Psychiatric conditions and inability to give informed consent Being on gluten free diet before entering the study Other cause of Hepatosteatosis

Design outcomes

Primary

Measure	Time frame
Liver steatosis grade. Timepoint: At the beginning of the study and three months later. Method of measurement: Ultrasound of the liver by a radiologist.;Lipid profile & fasting blood sugar. Timepoint: At the beginning of the study and three months later. Method of measurement: Serum level of lipid profile and fasting blood sugar after 12 hours of fasting, through blood test.;Weight & Body mass index. Timepoint: At the beginning of the study and three months later. Method of measurement: Using scales and calculating Body mass index using the corresponding formula.;Liver enzymes. Timepoint: At the beginning of the study and three months later. Method of measurement: Serum levels of liver enzymes.;Systolic blood pressure & diastolic blood pressure. Timepoint: At the beginning of the study and three months later. Method of measurement: Analog manometer.;Waist circumference. Timepoint: At the beginning of the study and three months later. Method of measurement: meter.	—

Measure

Time frame

Liver steatosis grade. Timepoint: At the beginning of the study and three months later. Method of measurement: Ultrasound of the liver by a radiologist.;Lipid profile & fasting blood sugar. Timepoint: At the beginning of the study and three months later. Method of measurement: Serum level of lipid profile and fasting blood sugar after 12 hours of fasting, through blood test.;Weight & Body mass index. Timepoint: At the beginning of the study and three months later. Method of measurement: Using scales and calculating Body mass index using the corresponding formula.;Liver enzymes. Timepoint: At the beginning of the study and three months later. Method of measurement: Serum levels of liver enzymes.;Systolic blood pressure & diastolic blood pressure. Timepoint: At the beginning of the study and three months later. Method of measurement: Analog manometer.;Waist circumference. Timepoint: At the beginning of the study and three months later. Method of measurement: meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Pashaee

Oroumia University of Medical Sciences

pashaee.m@umsu.ac.ir+98 44 3198 8001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026